Healthcare-associated infections in critical COVID-19 patients in Tunis: epidemiology, risk factors, and outcomes.
COVID-19
critical care
epidemiology
healthcare-associated infections
prognosis
Journal
Acute and critical care
ISSN: 2586-6060
Titre abrégé: Acute Crit Care
Pays: Korea (South)
ID NLM: 101726905
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
02
06
2023
accepted:
26
09
2023
medline:
6
12
2023
pubmed:
6
12
2023
entrez:
5
12
2023
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) pandemic disrupted adherences to healthcare-associated infection (HAI) prevention protocols. Herein, we studied the characteristics of all HAIs occurring in critically ill COVID-19 patients. A retrospective, single-center cohort of critical COVID-19 patients during 2021. Microbiological samples were collected if HAI was suspected. We analyzed all factors that could potentially induce HAI, using septic shock and mortality as endpoints. Sixty-four among 161 included patients (39.7%) presented a total of 117 HAIs with an incidence density of 69.2 per 1,000 hospitalization days. Compared to the prior COVID-19 period (2013-2019), the identification of HAI increased in 2021. HAIs were classified into ventilator-associated pneumonia (VAP; n=38), bloodstream infection (n=32), urinary tract infection (n=24), catheter-related infection (n=12), and fungal infection (n=11). All HAIs occurred significantly earlier in the post-COVID-19 period (VAP: 6 vs. 10 days, P=0.045, in 2017 and 2021). Acinetobacter baumannii (39.5%) and Klebsiella pneumoniae (27%) were the most commonly isolated pathogens that exhibited a multidrug-resistant (MDR) profile, observed in 89% and 64.5%, respectively. The HAI factors were laboratory abnormalities (odds ratio [OR], 6.4; 95% confidence interval [CI], 2.3-26.0), cumulative steroid dose (OR, 1.9; 95% CI, 1.3-4.0), and invasive procedures (OR, 20.7; 95% CI, 5.3-64.0). HAI was an independent factor of mortality (OR, 8.5; P=0.004). During the COVID-19 era, the incidence of HAIs increased and MDR isolates remained frequent. A severe biological inflammatory syndrome, invasive devices, and elevated cumulative steroid dosages were related to HAIs. HAI was a significant death factor.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (COVID-19) pandemic disrupted adherences to healthcare-associated infection (HAI) prevention protocols. Herein, we studied the characteristics of all HAIs occurring in critically ill COVID-19 patients.
METHODS
METHODS
A retrospective, single-center cohort of critical COVID-19 patients during 2021. Microbiological samples were collected if HAI was suspected. We analyzed all factors that could potentially induce HAI, using septic shock and mortality as endpoints.
RESULTS
RESULTS
Sixty-four among 161 included patients (39.7%) presented a total of 117 HAIs with an incidence density of 69.2 per 1,000 hospitalization days. Compared to the prior COVID-19 period (2013-2019), the identification of HAI increased in 2021. HAIs were classified into ventilator-associated pneumonia (VAP; n=38), bloodstream infection (n=32), urinary tract infection (n=24), catheter-related infection (n=12), and fungal infection (n=11). All HAIs occurred significantly earlier in the post-COVID-19 period (VAP: 6 vs. 10 days, P=0.045, in 2017 and 2021). Acinetobacter baumannii (39.5%) and Klebsiella pneumoniae (27%) were the most commonly isolated pathogens that exhibited a multidrug-resistant (MDR) profile, observed in 89% and 64.5%, respectively. The HAI factors were laboratory abnormalities (odds ratio [OR], 6.4; 95% confidence interval [CI], 2.3-26.0), cumulative steroid dose (OR, 1.9; 95% CI, 1.3-4.0), and invasive procedures (OR, 20.7; 95% CI, 5.3-64.0). HAI was an independent factor of mortality (OR, 8.5; P=0.004).
CONCLUSIONS
CONCLUSIONS
During the COVID-19 era, the incidence of HAIs increased and MDR isolates remained frequent. A severe biological inflammatory syndrome, invasive devices, and elevated cumulative steroid dosages were related to HAIs. HAI was a significant death factor.
Identifiants
pubmed: 38052509
pii: acc.2023.00773
doi: 10.4266/acc.2023.00773
doi:
Types de publication
Journal Article
Langues
eng
Pagination
425-434Références
Ann Intensive Care. 2020 Sep 7;10(1):119
pubmed: 32894364
Chest. 2021 Aug;160(2):454-465
pubmed: 33857475
Infect Drug Resist. 2018 Nov 15;11:2321-2333
pubmed: 30532565
Clin Infect Dis. 2021 Jul 15;73(2):e445-e454
pubmed: 32651997
Lancet Infect Dis. 2018 May;18(5):490-492
pubmed: 29695352
BMC Health Serv Res. 2018 Jul 4;18(1):521
pubmed: 29973258
Intensive Care Med. 2020 Dec;46(12):2168-2183
pubmed: 33175277
Curr Opin Clin Nutr Metab Care. 1999 Jan;2(1):79-82
pubmed: 10453334
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):495-502
pubmed: 33389263
Risk Manag Healthc Policy. 2020 Nov 13;13:2593-2599
pubmed: 33223859
Lancet Infect Dis. 2019 May;19(5):463-464
pubmed: 31034384
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720943331
pubmed: 32686571
Infect Control Hosp Epidemiol. 2020 Aug;41(8):982-983
pubmed: 32279676
Clin Infect Dis. 2020 Sep 12;:
pubmed: 32918466
Tunis Med. 2017 Mar;95(3):179-184
pubmed: 29446811
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Crit Care. 2022 Aug 3;26(1):236
pubmed: 35922860
Infect Control Hosp Epidemiol. 2022 Sep;43(9):1184-1193
pubmed: 34308805
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Microbiol Infect. 2021 Jan;27(1):83-88
pubmed: 32745596
Diabetes Care. 2019 May;42(5):832-840
pubmed: 30923164
Am J Infect Control. 2020 Oct;48(10):1211-1215
pubmed: 32093978
Antimicrob Resist Infect Control. 2021 Jun 4;10(1):87
pubmed: 34088341
J Hosp Infect. 2021 Jan;107:95-97
pubmed: 33217490